Researchers explore new treatments for a leading genetic cause of infant deaths

July 19, 2013

Researchers at Iowa State University have identified an RNA structure in humans that could lead to a new treatment for spinal muscular atrophy, the leading genetic cause of death in babies and young children.

Ravindra Singh, a professor of in the ISU College of Veterinary Medicine, is the lead author of a paper published this week in the journal Nucleic Acids Research that details the discovery of a novel that could be modified by medication, leading to new treatment possibilities for the disease.

Spinal results from the loss or mutation of a gene called Survival Motor Neuron 1, often referred to as SMN1. If SMN1 is deleted or doesn't function properly, not enough SMN protein is produced, giving rise to the disease.

Luckily, the vast majority of humans have a nearly identical gene, referred to as SMN2, which can function as a substitute. But a critical portion of SMN2 is sometimes erroneously removed during the process known as splicing, or when pre-mRNA is turned into mRNA by getting rid of non-functioning parts of the gene.

In the new paper, Singh and his colleagues have discovered an RNA structure exclusively formed by intronic sequences, or sequences that are removed during splicing. By targeting that structure, it may be possible to develop new treatments that prevent the mistake in the splicing process that causes the loss of function of SMN2, Singh said. If so, this is the first time a deep intronic structure can be targeted for therapy.

"About a quarter of a person's genome is made up of introns, or non-coding sequences, that must be removed through splicing throughout life," Singh said. "We've found an RNA structure that aberrantly promotes the escape of one of the coding sequences through splicing."

Singh cautioned that development of a new treatment would have to go through years of and further study, but the bottom line is that the research could result in a new way to cure . In fact, private companies have shown interest in negotiating with Iowa State to begin development of a drug based on the research, Singh said.

He said the paper required about five years of painstaking work, testing hundreds of to individual gene sequences one at a time to see if they have an effect on splicing.

"The process involves a lot of trial and error," he said.

Studying RNA structures within the non-coding portion of the human is still a relatively untouched frontier with much left to teach us, Singh said. It appears that RNA structures hold enormous information, and new techniques for studying RNA structures are unlocking new possibilities that could have major implications for how we treat genetic diseases, he said.

"In many ways this is still a very poorly understood field," Singh said. "But around half of all genetic diseases are a result of errors in splicing, so we have much to gain from answering these questions."

Explore further: Structure that edits messenger RNA transcripts defective in two different forms of motor neuron diseases

More information:

Related Stories

Recommended for you

Rac1 protein critical for lung development

October 20, 2016

A study by researchers from The Saban Research Institute of Children's Hospital Los Angeles reveals a promising therapeutic target for improving lung function in infants. Their study, now published online by the American ...

A vitamin could help treat Duchenne muscular dystrophy

October 19, 2016

Duchenne is the most common and severe form of muscular dystrophy. Because of this genetic disease, one out of every 3,500 children spends their 12th birthday in a wheelchair. This disorder progressively leads to general ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.